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Abstract
Background: Many studies have investigated the efficacy of Endostar combined with platinum-based doublet
chemotherapy (PBDC) versus PBDC alone for treating advanced non-small cell lung cancer (NSCLC). This study is a
meta-analysis of available evidence.
Methods: Fifteen studies reporting Endostar combined with PBDC versus PBDC alone for treating advanced NSCLC
were reviewed. Pooled odds ratios and hazard ratio with 95% confidence intervals were calculated using either the
fixed effects model or random effects model.
Results: The overall response rate (ORR) and disease control rate (DCR) of Endostar combined with PBDC for
treating NSCLC were significantly higher than those of PBDC alone, with 14.7% and 13.5% improvement,
respectively (P< 0.00001). In addition, the time to progression (TTP) and quality of life (QOL) were improved after
the treatment of Endostar combined with PBDC (P< 0.00001). The main adverse effects found in this review were
hematological reactions, hepatic toxicity, and nausea/vomiting. Endostar combined with PBDC had a similar
incidence of adverse reactions compared with PBDC alone (P< 0.05).
Conclusions: Endostar combined with PBDC was associated with higher RR, DCR, and TTP as well as superior QOL
profiles compared with PBDC alone. Endostar combined with PBDC had a similar incidence of adverse reactions
compared with PBDC alone.
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Background
Lung cancer is one of the most common malignancies in
the world. More than one million new cases are reported
globally every year, and the five-year survival rate is less
than 15% [1]. Non-small cell lung cancer (NSCLC) com-
prises 80% to 85% of lung cancer cases. Generally, 25% to
30% of NSCLC patients are in locally advanced stage upon
diagnosis, and 40% to 50% of patients have distant metasta-
ses, losing their opportunities for surgery [2]. The current
first-line chemotherapy options for patients with advanced
NSCLC, such as the combination of platinum-based agents
with paclitaxel, gemcitabine, vinorelbine, or docetaxel, have
substantial toxicity and seem to have reached a plateau in
terms of efficacy [3,4]. The use of cytotoxic chemotherapy
is associated with a response rate (RR) of 20% to 35% and a
median survival time of 10 to 12 months among patients
with advanced NSCLC [5]. Novel regimens are needed to
improve outcome, and the development of more effective
therapies remains challenging.
In recent years, the clinical application of antiangiogenic
therapy has brought promise for the treatment of NSCLC
and has become an important addition in the treatment of
tumor invasion and metastasis. In 1997, Folkman et al. first
identified endostatin, the 20 kD internal fragment of the
carboxyterminus of collagen XVIII, in the conditioned
media of hemangioendothelioma cells as an antiangiogenic
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molecule [6]. The direct target of endostatin is the new ca-
pillary endothelial cells around the tumor. Endostar (YH-
16), a novel recombinant human endostatin expressed and
purified in Escherichia coli, was approved by China’s State
Food and Drug Administration (SFDA) for the treatment
of NSCLC in 2005. Compared with rh-endostatin reported
in previous literature, an additional nine-amino acid se-
quence (MGGSHHHHH) was added at the N-terminal of
the protein, which resulted in the formation of a six-
histidine tag that could be chelated with metal ions such as
Ni2+ with a relatively high affinity. These changes simplified
the purification and improved the stability of the protein
[7,8]. However, the effect of the structural changes on the
antiangiogenic efficacy, including the mechanism of action,
remains unknown.
To date, several studies discuss the efficacy and safety of
Endostar in treating advanced lung cancer. Authentic as-
sessment of Endostar treatment in lung cancer is import-
ant and urgent. The current study presents a systematic
review to quantify the toxicities and clinical benefits of
Endostar combined with platinum-based doublet chemo-
therapy (PBDC) versus chemotherapy alone for treating
advanced NSCLC.
Methods
Search strategy and data extraction
An electronic search of scientific literature published in
the databases of MEDLINE/PubMed, EMBASE, Cochrane
Library, Science Citation Index, Current Controlled Trials,
and CNKI was performed using free text and Medical
Subject Heading terms such as ‘non-small cell lung can-
cer’, ‘NSCLC’, ‘lung adenocarcinoma’, ‘lung cancer’, ‘lung
squamous carcinoma’, ‘rh-endostatin’, ‘endostatin’, ‘chemo-
therapy’, ‘Endostar’, and ‘recombinant human endostatin
injection’. The search period was from the start of each
database up to July 2012 without language restrictions.
Moreover, a manual revision of the bibliographical refer-
ences of the selected articles was done. In addition to the
database search, papers were also identified by personal
contact with the authors using email and telephone as ne-
cessary. The extracted data are summarized as follows: (i)
general information, including the title, author, publication
date, and literature sources; (ii) design and implementa-
tion, including the type of design, research and follow-up
time, interventions, measurement indicator, the number
of lost and processed samples; and (iii) outcome indica-
tors, including RR, disease control rate (DCR), one-year
survival rate (OYS), time to progression (TTP), quality of
life (QOL), and adverse effects (AEs).
Criteria for inclusion and exclusion
Meta-analysis inclusion criteria were as follows: (i) trials
must compare Endostar combined with PBDC to PBDC
alone for treating advanced NSCLC; (ii) patients in the
studies meeting the first inclusion criteria must be diag-
nosed and confirmed by cytology and pathology; (iii) age
and gender must not be restricted; (iv) must report on at
least one of the outcome measures mentioned in the
succeeding portion of this study; (v) randomized phase
II and III studies were eligible if fully published; and (vi)
the total number of cases must be greater than or equal
to 40.
Abstracts, letters, editorials and expert opinions,
reviews without original data, and case reports were
excluded. The following studies were also excluded: (i)
those with no clearly reported outcomes of interest; (ii)
those evaluating patients with other types of malignant
tumors and did not contain a distinct group of patients
with NSCLC; and (iii) studies lacking control groups.
Type of trial design, interventions, and indicators to
determine efficacy
Trial design: randomized controlled trials of Endostar
combined with PBDC versus PBDC for treating advanced
NSCLC. Type of interventions: (i) Endostar + PBDC vs.
PBDC; (ii) Endostar substituted one or more drugs of
PBDC vs. PBDC; (iii) Endostar + PBDC A vs. PBDC B; and
(iv) Endostar + PBDC+ radiotherapy vs. PBDC+ radiother-
apy. Efficacy indicators: overall response rate (ORR), DCR,
OYS, TTP, QOL, and AEs (according to the toxicity cri-
teria of WHO).
Methodological quality assessment
The methodological quality for randomized controlled
trials (RCTs) was assessed using the criteria from the
Cochrane Handbook for Systematic Reviews of Interven-
tions (Version 5.0.1). The quality of trials was categor-
ized into low risk of bias, unclear risk of bias, or high
risk of bias. This categorization was according to the risk
for each important outcome within included trials, in-
cluding adequacy of the generation of allocation se-
quence, allocation concealment, blinding, and the
presence of incomplete outcome data, selective outcome,
or other sources of bias. The intention-to-treat (ITT)
analysis was also assessed for the randomized controlled
trials included in the present meta-analysis [9,10].
Statistical analysis
To assess the efficacy and safety of Endostar combined with
PBDC versus PBDC alone for treating advanced NSCLC,
two different meta-analysis approaches were used: a fixed
effects model and a random effects model. Dichotomous
variables were analyzed using estimation of odds ratios
(OR) and hazard ratio (HR) with a 95% confidence interval
(95% CI). The overall effect was tested using Z-scores, with
significance being set at P<0.05. Pooled effect was calcu-
lated using either the fixed effects model or random effects
model. Heterogeneity was evaluated through chi-square
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and I2. In the absence of statistically significant heterogen-
eity, the fixed effects method was used to combine the
results. When heterogeneity was confirmed, the random
effects method was used. Meta-regression was done to
evaluate whether results were different between two
groups. Sensitivity was analyzed by omitting each study
from the estimated pool conducted at each step. Finally,
publication bias was evaluated using funnel plots, the
Egger’s test, and the Begg’s test. Statistical analyses were
performed using SPSS (SPSS Institute, version 15.0, Chi-
cago, USA), RevMan 4.2 (The Cochrane Collaboration),
and Stata version 12.0 (Stata Corporation, TX, USA). All P-




Our systematic search identified 256 potentially relevant
abstracts, of which 88 were identified as requiring full-
text article retrieval. Close screening of these 88 studies
excluded 68 because of the following reasons: limited
cases (n < 40), non-human studies, and some received
Endostar therapy without a parallel control. Finally, 15
studies published between 2005 and 2012 matched the
inclusion criteria and were therefore included [11-25]
(Figure 1). A database was established according to the
extracted information from each selected paper. Table 1
shows the baseline demographic factors of the patients.
The eligible studies included 1953 patients, of whom
621 were women and 1332 were men. The sample sizes
oscillated between 46 [18] and 486 patients [11], and the
age of the patients mainly concentrated at the range of
40 to 70 years old, with the youngest at 18 years old [11]
and the oldest at 78 years old [20].
Quality of study design
The studies were appraised independently by two
authors (Li W and Ming ZJ) based on the criteria from
the Cochrane Handbook for Systematic Reviews of
Interventions (Version 5.0.1). According to our prede-
fined quality assessment criteria, six of the fifteen trials
(40%) were evaluated as having a low risk of bias, and
another nine included trials were evaluated as having an
unclear risk of bias. Table 2 shows the quality of each
study included in the present systematic review.
Comparison of ORR between Endostar combined with
PBDC and PBDC alone
Fifteen studies compared the ORR between Endostar
combined with PBDC and PBDC alone. The results of
the fixed effects model showed that OR= 1.69 (95% CI
1.39 to 2.05; test for heterogeneity = 4.53; I2 = 0%), test
for overall effect: Z = 5.02, P < 0.00001. The ORR of
Endostar combined with PBDC for treating NSCLC was
significantly higher than that of PBDC alone. The sub-
group analyses showed that ORR favored the following
five Endostar combinations with the overall effect Z-
value and P-values as follows: NP+Endostar versus NP
alone (Z = 4.61, P < 0.0001), GP + Endostar versus GP
alone (Z = 4.70, P < 0.0001), NP +Endostar + radiotherapy
versus NP+ radiotherapy (Z = 1.93, P < 0.05), TP/TC+
Endostar versus TP/TC alone (Z = 3.02, P < 0.05), and
NP/GP/TP/PP + Endostar versus NP/GP/TP/PP alone
(Z = 3.48, P < 0.05) (Figure 2). Sensitivity analyses showed
that the RR and 95% CI did not alter substantially by re-
moving any one trial (data not shown), with an OR pool
oscillating between 1.20 and 2.62.
Comparison of DCR between Endostar combined with
PBDC and PBDC alone
Fifteen studies compared the DCR between Endostar
combined with PBDC and PBDC alone. The results of
the fixed effects model showed that the OR was 1.22
(95% CI 1.06 to 1.41; Z = 2.77, P= 0.006). The DCR of
Endostar combined with PBDC for treating NSCLC was
significantly higher than that of PBDC alone. The sub-
group analyses showed that DCR favored the following
four Endostar combinations with the overall Z-value and
P-values as follows: NP+Endostar versus NP alone
(Z = 3.28, P= 0.001), GP +Endostar versus GP alone
(Z = 4.64, P < 0.0001), TP/TC+Endostar versus TP/TC
alone (Z = 3.32, P < 0.05), and NP/GP/TP/PP + Endostar
versus NP/GP/TP/PP alone (Z = 2.48, P < 0.05) (Figure 3).
In the analysis of sensitivity, the exclusion of studies in-
dividually did not substantially modify the estimators,
with an OR pool oscillating between 1.05 and 2.63.
Comparison of OYS and QOL between Endostar
combined with PBDC and PBDC alone
Five studies compared the OYS between Endostar com-
bined with PBDC and PBDC alone [15,18,20,21,24]. The
HR was 1.42 (95% CI 1.01 to 2.00; test for heterogeneity =
Figure 1 Flow chart of literature search. RCTs, randomized
controlled trials.
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Table 1 Patient characteristics of the clinical trials reviewed
Study N F/M Age
(Mean)
Histology (N) TNM Stage (N) Quality
of Life





Wang JW 2005 [11] 486 140/346 18-75 SCC (129) LAC (165)
Others (28)
IIIA (51) IIIB (81)
IV (185)
ECGO NPE versus NP +placebo 322 164 RR, DCR, TTP, SI, AEs
Yang L 2005 [12] 87 28/59 37-76 SCC (34) LAC (50)
Others (3)
III (32) IV (55) ECGO NPE versus NP 57 33 RR, DCR, SI, AEs
Cai L 2007 [13] 71 25/46 NA SCC (27) LAC (32)
Others (12)
IIIA (9) IIIB (33)
IV (29)
KPS NPE versus NP 39 32 RR, DCR, AEs
Mu HY 2009 [14] 62 22/40 42-75 SCC (28) LAC (34) IIIB (28) IV (34) KPS NPE versus NP (16) TPE versus
TP (6) PPE versus PP (8)
32 30 RR, DCR, SI, AEs
Liao HY 2009 [15] 85 32/53 36-72 SCC (36) LAC (49) IIIB (32) IV (53) KPS GPE versus GP 30 55 RR, DCR, OYS, AEs
Zang T 2009 [16] 104 36/68 42-68 NA IIIB (58) IV (46) ECGO GPE versus GP 48 56 RR, DCR, SI, AEs
Liu J 2009 [17] 62 17/45 29-68 SCC (38) LAC (24) III (37) IV (25) KPS NPE + RT versus NP+ RT 31 31 RR, DCR, TTP, AEs
Ma JB 2009 [18] 46 11/35 38-73 SCC (31) LAC (15) IIIA (26) IIIB (20) ECGO NPE+ RT versus NP+ RT 23 23 RR, DCR, TTP, AEs
Shi GY 2009 [19] 462 162/300 20-74 SCC (190) LAC (252)
Others (20)
IIIA (92) IIIB (144)
IV (226)
ECGO GPE versus GP 308 154 RR, DCR, TTP, SI, AEs
Han BH 2011 [20] 122 35/87 28-78 SCC (37) LAC (78)
Others (7)
IIIB (43) IV (79) ECGO TCE versus TC + placebo 61 61 RR, DCR, AEs
Zhao X 2011 [21] 69 23/46 35-73 SCC (34) LAC (25)
Others(10)
IIIB (11) IV (58) ECGO GPE versus GP 33 36 RR, DCR, AEs
Hu HT 2011 [22] 89 21/68 41-70 SCLC (89) NA KPS TPE versus TP 45 44 RR, DCR, AEs
Wen F 2011 [23] 84 27/57 54-75 SCC (36) LAC (44)
Others (4)
NA KPS NPE versus NP 43 41 RR, DCR, AEs
Zhang H 2011 [24] 56 15/41 36-75 SCC (18) LAC (33)
Others (5)
IIIB (32) IV (25) KPS NPE versus NP (2)
GPE versus GP (15)
TPE versus TP (11)
28 28 RR, DCR, TTP,
OYS, AEs




NA GPE versus GP 33 35 RR, DCR, SI
AEs , adverse effects; DCR, disease control rate; ECGO, eastern cooperative oncology group; F/M, female/male; GP, gemcitabine + cisplatin; GPE, gemcitabine + cisplatin + Endostar; Group 1, Endostar combined with PBDC;
Group 2, PBDC alone; KPS, Karnofsky physical status score; LAC, lung adenocarcinoma; N, number of patients; NA, not available; NP, vinorelbine + cisplatin; NPE, vinorelbine + cisplatin + Endostar; OYS, one-year survival
rate; PP, paclitaxel + cisplatin; PPE, paclitaxel + cisplatin + Endostar; RR, response rate; RT, radiotherapy; SCC, squamous cell carcinoma; SCLC, small-cell lung cancer; SI, symptom improvement; TC, paclitaxel + carboplatin;



















Table 2 Raw data and methodological quality of included trials










ITT Risk of bias
Wang JW 2005 [11] Multi-center Random number table (SAS) Insufficient Clear No No Unclear Yes Low risk of bias
Yang L 2005 [12] Multi-center Random number table (SPSS) Unclear Unclear Yes No Unclear No Unclear risk of bias
Cai L 2007 [13] Single center Random number table (SPSS) Unclear Clear Yes No Unclear No Low risk of bias
Mu HY 2009 [14] Single center Random number table (SPSS) Unclear Clear Yes No Unclear No Low risk of bias
Liao HY 2009 [15] Single center Random number table (SPSS) Unclear Unclear Yes No Unclear No Unclear risk of bias
Zhang T 2009 [16] Single center Random number table (SPSS) Unclear Clear Yes No Unclear No Low risk of bias
Liu J 2009 [17] Single center Random number table (SPSS) Unclear Unclear Yes No Unclear No Unclear risk of bias
Ma JB 2009 [18] Single center Random number table (SPSS) Unclear Unclear Yes Yes Unclear No Unclear risk of bias
Shi GY 2009 [19] Multi-center Random number table (SAS) Unclear Unclear Yes No Unclear No Unclear risk of bias
Han BH 2011 [20] Multi-center Random number table (SPSS) Insufficient Clear Yes No Unclear No Low risk of bias
Zhao X 2011 [21] Single center Random number table (SPSS) Unclear Clear Yes No Unclear No Low risk of bias
Hu HT 2011 [22] Single center Random number table (SPSS) Unclear Unclear Yes No Unclear No Unclear risk of bias
Wen F 2011 [23] Single center Random number table (SPSS) Unclear Unclear Yes No Unclear No Unclear risk of bias
Zhang H 2011 [24] Multi-center unclear Unclear Unclear Yes No Unclear No Unclear risk of bias
Chen Q 2011 [25] Single center Random number table (SPSS) Unclear Unclear Yes No Unclear No Unclear risk of bias
ITT, intention-to-treat; SAS, SAS software; SPSS, SPSS software.
Figure 2 ORR of Endostar combined with PBDC versus PBDC alone for treating NSCLC. GP, gemcitabine + cisplatin;
NP, vinorelbine + cisplatin; OR, odds ratio; ORR, overall response rate; PBDC, platinum-based doublet chemotherapy; PP, paclitaxel + cisplatin;
RT, radiotherapy; TC, paclitaxel + carboplatin; TP, docetaxel + cisplatin.
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14.14; I2 = 0%), test for overall effect: Z = 5.24, P < 0.0001
(Figure 4). The OYS of Endostar combined with PBDC
for treating NSCLC was higher than that of PBDC alone.
Five trials involving 742 patients compared the QOL
between Endostar combined with PBDC and PBDC alone
for treating advanced NSCLC [14,16,18,19,25]. The results
showed that the OR was 1.86 (95% CI 1.47 to 2.35; test for
heterogeneity = 13.19; I2 = 47.7%), test for overall effect:
Z= 4.65, P< 0.00001 (Figure 4). The QOL improvement of
Endostar combined with PBDC for treating NSCLC was
significantly higher than that of PBDC alone.
Comparison of TTP between Endostar combined with
PBDC versus PBDC alone
Five studies reported prolonged TTP for randomized con-
trolled trials of Endostar combined with PBDC versus
PBDC alone for treating advanced NSCLC [11,12,17,19,24].
The results showed that the mean±SD TTP of Endostar
combined with PBDC versus PBDC alone was 6.19±0.80
and 3.83±0.73 months, respectively. The t-value was 12.02;
the degree of freedom was 4, P<0.00001 (Table 3). The
TTP of Endostar combined with PBDC for treating NSCLC
was significantly longer than that of PBDC alone (Figure 5).
Comparison between Endostar combined with PBDC and
PBDC alone by different stratifications
Two trials conducted a statistical analysis of the different
stratifications of the patients such as sex, histology,
TNM stage, and treatment history. One study [11] indi-
cated that male patients with squamous cell carcinoma
and lung adenocarcinoma showed higher RR after re-
ceiving Endostar combined with PBDC compared with
PBDC alone (P= 0.001, P= 0.009, P= 0.007, respectively).
Regardless of whether the patients had a history of treat-
ment, those who received Endostar combined with
PBDC had a higher RR (P= 0.003, P= 0.034, respect-
ively). However, another trial [12] did not find significant
differences in those stratifications (Table 4).
Adverse reactions analysis of Endostar combined with
PBDC versus PBDC alone
Included trials assessed 11 serious AEs, the most common
being gastrointestinal, skin-related, and hematologic
Figure 3 DCR of Endostar combined with PBDC versus PBDC alone for treating NSCLC. DCR, disease control rate;
GP, gemcitabine + cisplatin; NP, vinorelbine + cisplatin; OR, odds ratio; PBDC, conventional platinum-based doublet chemotherapy;
PP, paclitaxel + cisplatin; RT, radiotherapy; TC, paclitaxel + carboplatin; TP, docetaxel + cisplatin.
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diseases. Twelve studies compared the grade 3 or 4
leukopenia and thrombocytopenia between Endostar com-
bined with PBDC and PBDC alone [11-16,19-21,23-25].
The Endostar combination arms had a similar incidence
of grade 3 or 4 leukopenia relative to the PBDC arms
(OR=0.86, 95% CI 0.70 to 1.06, P=0.165). No difference
in thrombocytopenia incidence was found between
Endostar combined with PBDC and PBDC alone (OR=
0.89, 95% CI 0.72 to 1.11, P= 0.305) (Figure 6). No sig-
nificant differences in incidence and severity were found
between Endostar combined with PBDC and PBDC alone
(Figure 7) in 10 studies comparing anemia [11-16,19-
21,25] (OR=0.95, 95% CI 0.78 to 1.14, P= 0.562) and in
11 studies comparing nausea/vomiting [11,13-16,19-
21,23-25] (OR=0.96, 95% CI 0.81 to 1.14, P=0.649).
Other common AEs including diarrhea, skin rash, dys-
function of liver, constipation, alopecia, nerve toxicity, and
mucositis occurred with similar incidence in the two
groups (P> 0.05).
Analysis of publication bias
In the present study, the shape of the funnel plot
appeared to be approximately symmetrical and sug-
gested that publication biases may not have a significant
effect on the results. The result of the Egger’s test was
t = 0.51 (P= 0.618), whereas that of the Begg’s test was
SD of score = 20.21 (P= 0.619). Therefore, both tests
suggested that publication biases may not have a signifi-
cant effect on the results (Figure 8).
Figure 4 OYS and QOL improvement of Endostar combined with PBDC versus PBDC alone for treating NSCLC. HR, hazard ratio; OR, odds
ratio; OYS, one-year survival rate; PBDC, conventional platinum-based doublet chemotherapy; QOL, quality of life.





T-value 95% CI P-value
Wang JW 2005 [11] 6.3 3.6 T = 12.02 1.815
to 2.91
0.000
Yang L 2005 [12] 5.03 3.33
Liu J 2009 [17] 6.2 3.4
Shi GY 2009 [19] 6.1 3.7 df = 4
Zhang H 2011 [24] 7.3 5.1
Mean± SD 6.19 ± 0.80 3.83 ± 0.73
95% CI, 95% confidence interval; df, degree of freedom; SD, standard deviation; TTP, time to progression.
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Discussion
The angiogenesis inhibitors for the treatment of cancer as
a new approach are based on Folkman’s theory in 1971
[26]. Since then, hundreds of angiogenesis inhibitors were
discovered and used in drug development. Endostatin
specifically acts on neovascular endothelial cells, inhibits
cell migration, and induces cell apoptosis, thus playing a
major antiangiogenic role by acting on tumor-associated
neovascular endothelial cells [27]. Endostar, a novel re-
combinant human endostatin expressed and purified in
E. coli with an additional nine-amino acid sequence and
forming another histidine-tag structure, was approved
by the SFDA in 2005 for the treatment of NSCLC [8].
In 2005, SFDA licensed Endostar plus NP to treat
advanced NSCLC as a first-line therapy. The decision
was mainly based on a phase III study [11], which was
a randomized, double-blind, multicenter trial comparing
treatment with NP plus endostar and NP alone, first-
line, in advanced NSCLC patients.
In recent years, several studies have reported on the
efficacy and safety of Endostar in the treatment of
advanced lung cancer. This systematic review was per-
formed to quantify better the benefits and toxicities of
Endostar combined with PBDC versus PBDC alone for
treating advanced NSCLC. In this review, 15 reports of
randomized trials were identified by searching from the
start of each database up to July 2012. A significant
benefit of Endostar plus PBDC in ORR was found
(OR= 1.69, 95% CI 1.39 to 2.05), translating into a
14.7% (40.3% to 25.6%) absolute improvement. A meta-
analysis of DCR was also conducted (OR= 1.22, 95%
CI 1.06 to 1.41). A 13.5% improvement (from 64.7% to
78.2%) of Endostar plus PBDC was found compared
with PBDC alone. NP plus Endostar versus NP, GP
plus Endostar versus GP, NP plus Endostar plus radio-
therapy versus NP plus radiotherapy, and TP/TC plus
Endostar versus TP/TC showed improvements of
16.5%, 14.7%, 16.7%, and 19.5% in ORR, respectively,
and 10.6%, 16%, 9.5%, and 18.2% in DCR, respectively.
From the five reports in the present study, the one-
year survival rates in the groups of Endostar plus
PBDC and the PBDC alone were 55.4% and 45.3%, re-
spectively, reflecting a 10.1% improvement. Five reports
analyzed that the TTP of Endostar combined with
PBDC (6.19 ± 0.80 months) for treating NSCLC was
significantly longer than that of PBDC alone
(3.83 ± 0.73 months). However, only five trials providing
Figure 5 TTP of Endostar combined with PBDC versus PBDC
alone for treating NSCLC. PBDC, conventional platinum-based
doublet chemotherapy; TTP, time to progression.
Table 4 Comparison of Endostar with PBDC versus PBDC alone by different stratifications
Item Wang JW 2005 [11] Yang L 2005 [12]
Group 1 N (%) Group 2 N (%) P-value Group 1 N (%) Group 2 N (%) P-value
Sex
Male 74 (32.3) 19 (16.2) 0.001 - - -
Female 40 (43.0) 13 (27.7) 0.08 - - -
Histology
SCC 49 (38.0) 10 (18.2) 0.009 11 (47.8) 3 (30) 0.476
LAC 54 (32.7) 17 (17.3) 0.007 6 (22.2) 5 (21.7) 1.000
Others 11 (39.3) 5 (45.5) 0.72
TNM stage
IIIA 17 (33.3) 5 (16.7) 0.11 10 (52.6) 3 (23.1) 0.147
IIIB 29 (33.7) 10 (22.2) 0.17
IV 68 (36.8) 17 (19.1) 0.003 9 (25.7) 5 (25) 1.000
Treatment history
No 92 (40.0) 28 (23.9) 0.003 10 (37) 4 (19) 0.214
Yes 22 (23.9) 4 (8.5) 0.034 10 (37) 4 (33.3) 1.000
Group 1, Endostar combined with PBDC; Group 2. PBDC alone; LAC, lung adenocarcinoma; SCC, squamous cell carcinoma.
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relative data were included, which were insufficient to
reach a decisive conclusion. Therefore, more research
is required to gain a clear understanding of the prob-
ability. In the E4599 and AVAIL studies, the antiangio-
genesis agent bevacizumab plus chemotherapy not only
increased ORR, but also improved PFS [28,29]. The
combination of rh-endostatin with vinorelbine plus cis-
platin or paclitaxel plus carboplatin chemotherapy
enhanced the antitumor effect in two large multicenter
phase III trials in advanced NSCLC patients [30,31].
The results of present study are consistent with those
of reported studies.
The benefit of chemotherapy in incurable cancers
needs to be assessed directly through validated health-
related QOL instruments, rather than inferred from
RRs, survival benefits, and other traditional endpoints
[32]. In the present study, 742 eligible patients were en-
rolled in the assessment of QOL. A significant benefit of
Endostar plus PBDC in the overall improvement rate of
QOL (OR= 3.93, 95% CI 2.78 to 5.56) was found, trans-
lating into a 29.5% (52.3% to 22.8%) absolute improve-
ment. This prospective QOL analysis supports the
clinical benefit of the addition of bevacizumab to 5-
fluorouracil-based chemotherapy in improving time to
disease progression and prolonging overall survival,
without compromising the patients’ QOL [32]. In clin-
ical settings, phase I and phase II studies revealed that
Endostar was effective as a single agent with good toler-
ance in pretreated advanced NSCLC patients at a dose
of 7.5 mg/m2 daily. Special attention should be given to
toxic effects typically observed in antiangiogenesis treat-
ment. The AEs found in the present review were mainly
hematological reactions, diarrhea, hepatic toxicity, and
nausea/vomiting, most of which were grade 1 or 2 and
were well tolerated. The results supported that the
Endostar combination arms had a similar incidence of
AEs compared with PBDC alone. Although no signifi-
cant differences were found between the two groups,
incidences of hematological reactions and nausea/vomit-
ing were slightly higher in the control group (PBDC
alone). Whether Endostar combination could relieve the
AEs of treatment should be followed up in future stud-
ies. Overall, these results indicate that the potential
benefit of Endostar may be widely applicable to a patient
Figure 6 Meta-analysis of the severe leukopenia and thrombocytopenia between Endostar combined with PBDC and PBDC alone.
OR, odds ratios; PBDC, conventional platinum-based doublet chemotherapy.
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population closely resembling clinical reality in advanced
NSCLC.
Addressing statistical heterogeneity is one of the most
important aspects of systematic reviews. The interpret-
ative problems are dependent on heterogeneity because
it might affect the conclusions of the meta-analysis.
Therefore, heterogeneity among the collection of studies
must be quantified. In this review, the included studies
were carefully assessed. A good clinical homogeneity
was confirmed, and publication bias was not found
according to the funnel plot analysis, the Egger’s test,
and the Begg’s test. However, some deficiencies in the
present meta-analysis were found. First, the quality of
subgroup analysis (age, sex, smoking, histology, and
treatment status) according to the different agents
(Endostar plus PBDC compared with PBDC) was low
because the subgroup data were only provided by a few
trials. Only two trials fulfilling the subgroup analysis
were included, which were insufficient to reach a de-
cisive conclusion. Second, some reports failed to report
the method for concealment of allocation, blinding, and
ITT. In addition, the partial reports comprise a small
sample size, and some of the reports’ experimental
control is not very balanced. Most of the included stud-
ies were published in Chinese, with heterogeneous data
and analysis methods (for example, the different scored
scales were used to assess the life quality). In addition,
the number of cases available was relatively small.
Hence, the validity of the results was compromised. Al-
though such studies were reported to be of low quality,
they still contain credible evidence pointing toward such
new drugs. Clinical trials are expensive and difficult.
Hence, these findings can help choose the most promis-
ing agents for study. However, Endostar, as a new strat-
egy, still has many issues to be resolved in further
studies. Confirmation of these conclusions in rigorously
controlled randomized trials is required before firm con-
clusions about this therapy can be drawn.
Conclusion
The results showed that Endostar combined with PBDC
was associated with higher ORR, DCR, and TTP as well
as superior QOL profiles as compared with PBDC alone.
Moreover, Endostar combined with PBDC was shown to
slightly decrease AEs. Endostar combined with PBDC
exhibited superior efficacy and safety in antiangiogenesis
Figure 7 Meta-analysis of anemia and nausea/vomiting between Endostar combined with PBDC and PBDC alone. OR, odds ratios;
PBDC, conventional platinum-based doublet chemotherapy.
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treatment compared with PBDC alone. However, Endo-
star, as a new strategy, still has many issues to be resolved
in further studies. The notable efficacy and activity of
Endostar in combination with PBDC suggest that this
regimen may have a value in the treatment of previously
untreated patients, including those who cannot tolerate
more aggressive therapies. However, confirmation of
these conclusions in rigorously controlled randomized
trials is required before firm conclusions about this ther-
apy can be drawn.
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